drugset / Trial / NCT01199302

Long-term Safety Study of Brodalumab in Adults With Crohn's Disease

NCT01199302

Phase 2 Terminated 67 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of long-term treatment with brodalumab in adults with Crohn's disease.

Timeline

Start
2011-02-02
Primary completion
2011-10-18
Completion
2011-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Brodalumab Monoclonal antibody 350 mg Intravenous

Indications